文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

使用3'-脱氧-3'[(18)F]-氟胸苷（F-FLT）PET/CT对肺癌靶向治疗的早期反应评估

Early Response Assessment to Targeted Therapy Using 3'-deoxy-3'[(18)F]-Fluorothymidine (F-FLT) PET/CT in Lung Cancer.

作者信息

Kairemo Kalevi, Santos Elmer B, Macapinlac Homer A, Subbiah Vivek

机构信息

Department of Nuclear Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.

Investigational Cancer Therapeutics, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.

出版信息

Diagnostics (Basel). 2020 Jan 6;10(1):26. doi: 10.3390/diagnostics10010026.

DOI:10.3390/diagnostics10010026
PMID:31935818
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7169847/
Abstract

Although 2-deoxy-2-[18F]-fluoro-D-glucose positron emission tomography/computed tomography (F-FDG PET/CT) is a sensitive nuclear medicine modality, specificity for characterizing lung cancer is limited. Tumor proliferation and early response to molecularly targeted therapy could be visualized using 3'-deoxy-3'[(18)F]-fluorothymidine (F-FLT) PET/CT. The superiority of F-FLT PET/CT over F-FDG PET/CT in early therapeutic monitoring has been well described in patients after chemotherapy, radiotherapy, and/or chemo/radiotherapy. In thispilot study, we explorethe use of F-FLT PET/CT as an early response evaluation modality in patients with lung cancerand provide specific case studies of patients with small cell lung cancer and non-small cell lung cancer who received novel targeted therapies. Early response for c-MET inhibitor was observed in four weeks and for MDM2 inhibitor in nine days.

摘要

尽管2-脱氧-2-[18F]-氟-D-葡萄糖正电子发射断层扫描/计算机断层扫描（F-FDG PET/CT）是一种敏感的核医学检查方法，但用于肺癌特征性诊断的特异性有限。使用3'-脱氧-3'-[(18)F]-氟胸苷（F-FLT）PET/CT可观察到肿瘤增殖及对分子靶向治疗的早期反应。在化疗、放疗和/或放化疗后的患者中，F-FLT PET/CT在早期治疗监测方面优于F-FDG PET/CT，这一点已有充分描述。在这项前瞻性研究中，我们探索将F-FLT PET/CT用作肺癌患者早期反应评估方法，并提供接受新型靶向治疗的小细胞肺癌和非小细胞肺癌患者的具体病例研究。观察到c-MET抑制剂治疗四周出现早期反应，MDM2抑制剂治疗九天出现早期反应。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0aca/7169847/6e53e49d3c13/diagnostics-10-00026-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0aca/7169847/299cadb089c9/diagnostics-10-00026-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0aca/7169847/ff2570b40789/diagnostics-10-00026-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0aca/7169847/6e53e49d3c13/diagnostics-10-00026-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0aca/7169847/299cadb089c9/diagnostics-10-00026-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0aca/7169847/ff2570b40789/diagnostics-10-00026-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0aca/7169847/6e53e49d3c13/diagnostics-10-00026-g003.jpg

相似文献

[1]
Early Response Assessment to Targeted Therapy Using 3'-deoxy-3'[(18)F]-Fluorothymidine (F-FLT) PET/CT in Lung Cancer.

Diagnostics (Basel). 2020-1-6

[2]
Molecular Imaging with 3'-deoxy-3'[(18)F]-Fluorothymidine (F-FLT) PET/CT for Early Response to Targeted Therapies in Sarcomas: A Pilot Study.

Diagnostics (Basel). 2020-2-25

[3]
Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.

Radiother Oncol. 2010-11-4

[4]
Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer.

Int J Radiat Oncol Biol Phys. 2009-11-15

[5]
An Assessment of Early Response to Targeted Therapy via Molecular Imaging: A Pilot Study of 3'-deoxy-3'[(18)F]-Fluorothymidine Positron Emission Tomography F-FLT PET/CT in Prostate Adenocarcinoma.

Diagnostics (Basel). 2017-4-4

[6]
Can 3'-deoxy-3'-(18)F-fluorothymidine or 2'-deoxy-2'-(18)F-fluoro-d-glucose PET/CT better assess response after 3-weeks treatment by epidermal growth factor receptor kinase inhibitor, in non-small lung cancer patients? Preliminary results.

Hell J Nucl Med. 2014

[7]
3'-Deoxy-3'-18F-fluorothymidine as a proliferation imaging tracer for diagnosis of lung tumors: comparison with 2-deoxy-2-18f-fluoro-D-glucose.

J Comput Assist Tomogr. 2008

[8]
Comparison of Positron Emission Tomography Using 2-[18F]-fluoro-2-deoxy-D-glucose and 3-deoxy-3-[18F]-fluorothymidine in Lung Cancer Imaging.

Chin Med J (Engl). 2016-12-20

[9]
Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer.

J Nucl Med. 2014-5-15

[10]
Interobserver agreement of qualitative analysis and tumor delineation of 18F-fluoromisonidazole and 3'-deoxy-3'-18F-fluorothymidine PET images in lung cancer.

J Nucl Med. 2013-8-5

引用本文的文献

[1]
Hypoxia Imaging in Lung Cancer: A PET-Based Narrative Review for Clinicians and Researchers.

Pharmaceuticals (Basel). 2025-3-25

[2]
Recent developments in translational imaging of in vivo gene therapy outcomes.

Mol Ther. 2025-6-4

[3]
Deciphering Tumor Response: The Role of Fluoro-18-d-Glucose Uptake in Evaluating Targeted Therapies with Tyrosine Kinase Inhibitors.

J Clin Med. 2024-5-31

[4]
Role of 3'-Deoxy-3'-[F] Fluorothymidine Positron Emission Tomography-Computed Tomography as a Predictive Biomarker in Argininosuccinate Synthetase 1-Deficient Thoracic Cancers Treated With Pegargiminase.

JTO Clin Res Rep. 2022-7-20

[5]
"How Long Have I Got?" in Stage IV NSCLC Patients With at Least 3 Months Up to 10 Years Survival, Accuracy of Long-, Intermediate-, and Short-Term Survival Prediction Is Not Good Enough to Answer This Question.

Front Oncol. 2021-12-21

[6]
Novel Tracers and Radionuclides in PET Imaging.

Radiol Clin North Am. 2021-9

[7]
Imaging Biomarkers of Tumour Proliferation and Invasion for Personalised Lung Cancer Therapy.

J Pers Med. 2020-11-12

[8]
Imaging for Response Assessment in Cancer Clinical Trials.

Semin Nucl Med. 2020-11

本文引用的文献

[1]
FLT-PET-CT for the Detection of Disease Recurrence After Stereotactic Ablative Radiotherapy or Hyperfractionation for Thoracic Malignancy: A Prospective Pilot Study.

Front Oncol. 2019-5-31

[2]
Predictive value of positron emission tomography for the prognosis of molecularly targeted therapy in solid tumors.

Onco Targets Ther. 2018-12-7

[3]
C-MET inhibitors for advanced non-small cell lung cancer.

Expert Opin Investig Drugs. 2018-4-11

[4]
The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer.

Clin Cancer Res. 2017-5-30

[5]
Correlations of 18F-FDG and 18F-FLT uptake on PET with Ki-67 expression in patients with lung cancer: a meta-analysis.

Acta Radiol. 2018-2

[6]
The role of new PET tracers for lung cancer.

Lung Cancer. 2016-4

[7]
A systematic review on [(18)F]FLT-PET uptake as a measure of treatment response in cancer patients.

Eur J Cancer. 2016-3

[8]
MET Exon 14 Mutations in Non-Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression.

J Clin Oncol. 2016-1-4

[9]
Performance of FLT-PET for pulmonary lesion diagnosis compared with traditional FDG-PET: A meta-analysis.

Eur J Radiol. 2015-7

[10]
Comparison of the diagnostic performance of F-fluorothymidine versus F-fluorodeoxyglucose positron emission tomography on pulmonary lesions: A meta analysis.

Mol Clin Oncol. 2015-1

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索